AKBA Reports $52M Q1 Revenue, $15.8M Vafseo Sales, +60% Patients, 28% More Prescribers, Praliciguat Phase 2 Enrollment, R&D Day Pipeline Update
Akebia Therapeutics, Inc. · PHARMACEUTICAL PREPARATIONS · Now $1.02
-14% in 7d after detection
Post-detection moves
1h
—
1d
-1.7%
3d
0.0%
7d
-14%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS